interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Olezarsen Sodium

Generic competition · all medicines · read 12 November 2026

Is there a generic of Olezarsen Sodium, and who makes it?

Olezarsen Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Olezarsen Sodium1 dosage-form group in the Orange Book
0generic makers listed
  1. Olezarsen Sodium appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Tryngolza (Autoinjector). No generic is listed as marketed.

202020252030203501brand 2024data datePatent 9157082 listed to expire 27 April 2032Patent 9593333 listed to expire 14 February 2034Patent 12509684 listed to expire 1 May 2034Patent 9181549 listed to expire 1 May 2034Patent 9127276 listed to expire 1 May 2034Patent 9163239 listed to expire 1 May 2034Exclusivity NS to 24 June 2029Exclusivity I-992 to 24 June 2029Exclusivity ODE-515 to 19 December 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 24 June 2029Exclusivity NS Tryngolza (Autoinjector)
  • 24 June 2029Exclusivity I-992 Tryngolza (Autoinjector)
  • 19 December 2031Exclusivity ODE-515 Tryngolza (Autoinjector)
  • 27 April 2032Patent 9157082
  • 14 February 2034Patent 9593333
  • 1 May 2034Patent 12509684
  • 1 May 2034Patent 9181549 drug substance
  • 1 May 2034Patent 9127276 drug substance
  • 1 May 2034Patent 9163239 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.